IP Library Granted Patent US 11,225,685
Granted Patent B2
US 11,225,685 · App. 16/815,963 · Granted Jan 18, 2022

Methods and materials for assessing allelic imbalance

Inventors: Alexander Gutin (Salt Lake City, UT); Kirsten Timms (Salt Lake City, UT); Jerry Lanchbury (Salt Lake City, UT)
Assignee: MYRIAD GENETICS, INC.
C12Q1/6827C12Q1/6858C12Q1/6874C12Q1/6883G16B30/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,225,685
App. No.
16/815,963
Granted
Jan 18, 2022
Kind
B2
Abstract

Methods and systems for detecting allelic imbalance using nucleic acid sequencing are provided.

Claims (28)

1. An in vitro method of detecting loss of heterozygosity (LOH) status in a plurality of single nucleotide polymorphism (SNP) genomic loci in a formalin-fixed paraffin-embedded tissue sample from a patient, comprising:

enriching a genomic DNA sample for DNA molecules each comprising a SNP locus of interest, wherein there is at least one SNP locus located on average every 5 Mb within each chromosome that is examined;

sequencing the DNA molecules to determine the genotype at each such SNP locus;

determining for each homozygous SNP locus whether it is homozygous due to LOH.

2. The method of claim 1 , wherein there is at least one SNP locus located on average every 1 Mb within each chromosome that is examined.

3. The method of claim 1 , wherein the plurality of genomic SNP loci comprises at least 5,000 more loci.

4. The method of claim 1 , wherein the plurality of genomic SNP loci comprises at least 10,000 more loci.

5. The method of claim 1 , wherein a SNP locus is determined to have allelic imbalance if the major copy proportion at the SNP locus is 0.51 or greater.

6. The method of claim 1 , wherein the SNP genomic loci are evenly spaced along the genome.

7. The method of claim 6 , wherein the percentage difference between the distance between any two of the plurality of SNP genomic loci and the distance between any other two of the plurality of SNP loci is less than or equal to 20%.

8. The method of claim 1 , wherein the sample is a tumor sample extracted from the patient.

9. The method of claim 8 , wherein the tumor sample comprises at least 5%, or more contamination with non-tumor cells.

10. The method of claim 1 , wherein there is at least one single nucleotide polymorphism locus located on average every 500 kb within each chromosome.

11. A system for determining LOH status in a plurality of SNP genomic loci in a formalin-fixed paraffin-embedded tissue sample, wherein the system comprises:

a sample analyzer configured to

enrich a genomic DNA sample for DNA molecules, each test DNA molecule comprising a SNP locus of interest and wherein there is at least one SNP locus located on average every 5 Mb within each chromosome that is examined;

sequencing the DNA molecules to produce a plurality of quantitative signals for each such SNP locus;

a computer program that is configured to analyze the plurality of quantitative signals to determine the genotype of each such SNP locus in the sample; and

a computer program that is configured to determine, for each homozygous SNP locus, whether the locus is homozygous due to LOH.

12. The system of claim 11 , wherein there is at least one SNP locus located on average every 1 Mb within each chromosome that is examined.

13. The system of claim 11 , wherein the plurality of genomic SNP loci comprises at least 5,000 more loci.

14. The system of claim 11 , wherein the plurality of genomic SNP loci comprises at least 10,000 more loci.

15. The system of claim 11 , wherein a SNP locus is determined to have allelic imbalance if the major copy proportion at the SNP locus is 0.51 or greater.

16. The system of claim 11 , wherein the SNP genomic loci are evenly spaced along the genome.

17. The system of claim 16 , wherein the percentage difference between the distance between any two of the plurality of SNP genomic loci and the distance between any other two of the plurality of SNP loci is less than or equal to 20%.

18. The system of claim 11 , wherein the sample is a tumor sample extracted from the patient.

19. The system of claim 18 , wherein the tumor sample comprises at least 5%, or more contamination with non-tumor cells.

20. The system of claim 11 , wherein there is at least one single nucleotide polymorphism locus located on average every 500 kb within each chromosome.

Assignments (4)
SECURITY INTEREST Recorded Aug 1, 2025
From: MYRIAD GENETICS, INC.; MYRIAD GENETIC LABORATORIES, INC.; MYRIAD WOMEN’S HEALTH, INC.; ASSUREX HEALTH, INC.; GATEWAY GENOMICS, LLC
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP, AS ADMINISTRATIVE AGENT FOR SECURED PARTIES
Reel/Frame 072309/0932 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (064235/0032) Recorded Aug 1, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: MYRIAD GENETICS, INC.; MYRIAD WOMEN’S HEALTH, INC.; GATEWAY GENOMICS, LLC; ASSUREX HEALTH, INC.
Reel/Frame 072331/0215 →
PATENT SECURITY AGREEMENT Recorded Jul 7, 2023
From: MYRIAD GENETICS, INC.; MYRIAD WOMEN'S HEALTH, INC.; GATEWAY GENOMICS, LLC; ASSUREX HEALTH, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 064235/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2021
From: GUTIN, ALEXANDER; TIMMS, KIRSTEN; LANCHBURY, JERRY
To: MYRIAD GENETICS, INC.
Reel/Frame 057864/0069 →
Continuity (6)
Continuation 15412404 · Jan 23, 2017
Continuation 15010721 · Jan 29, 2016
Continuation 14109163 · Dec 17, 2013
Continuation PCTUS2012042668 · Jun 15, 2012
Provisional Application 61498418 · Jun 17, 2011
Related Publication 20200239943A1 · Jul 30, 2020